TP53 mutations, expression and interaction networks in human cancers
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
// Xiaosheng Wang 1 , Qingrong Sun 2 1 Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China 2 School of Science, China Pharmaceutical University, Nanjing 211198, China Correspondence to: Xiaosheng Wang, email: xiaosheng.wang@cpu.edu.cn Keywords: TP53 mutations, TP53 expression, TP53 interaction networks, human cancers, synthetic lethality Received: July 22, 2016 Accepted: November 14, 2016 Published: November 21, 2016 ABSTRACT Although the associations of p53 dysfunction, p53 interaction networks and oncogenesis have been widely explored, a systematic analysis of TP53 mutations and its related interaction networks in various types of human cancers is lacking. Our study explored the associations of TP53 mutations, gene expression, clinical outcomes, and TP53 interaction networks across 33 cancer types using data from The Cancer Genome Atlas (TCGA). We show that TP53 is the most frequently mutated gene in a number of cancers, and its mutations appear to be early events in cancer initiation. We identified genes potentially repressed by p53, and genes whose expression correlates significantly with TP53 expression. These gene products may be especially important nodes in p53 interaction networks in human cancers. This study shows that while TP53 -truncating mutations often result in decreased TP53 expression, other non-truncating TP53 mutations result in increased TP53 expression in some cancers. Survival analyses in a number of cancers show that patients with TP53 mutations are more likely to have worse prognoses than TP53 -wildtype patients, and that elevated TP53 expression often leads to poor clinical outcomes. We identified a set of candidate synthetic lethal (SL) genes for TP53 , and validated some of these SL interactions using data from the Cancer Cell Line Project. These predicted SL genes are promising candidates for experimental validation and the development of personalized therapeutics for patients with TP53 -mutated cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
STRING v9.1: protein-protein interaction networks, with increased coverage and integration
Franceschini, A., Szklarczyk, D., Frankild, S., Kuhn, M., Simonovic, M., Roth, A., Lin, J., Minguez, P., Bork, P., von Mering, C., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1094 · Cited by 4,398
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967 · cited 1×
“Although the associations of p53 dysfunction, p53 interaction networks, and oncogenesis have been widely explored [5], a systematic analysis of TP53 mutations and the related interaction networks in various types of human cancers is lacking.”
BackgroundZhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“The explanation for these results could be that some TP53 mutations result in overexpression of mutant forms of TP53 while other mutations simply inactivate TP53 [12].”
BackgroundMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · cited 1×
“Some therapeutic strategies have been proposed to treat TP53-mutated cancers, such as restoring wild-type activity to; promoting the degradation of; or targeting pathways regulated by mutant p53 [9].”
BackgroundThe Cell–Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
Chen, J. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026104 · Cited by 1,222 · cited 1×
“Supplementary Table S5 shows that these gene products are significantly involved in p53-related pathways such as cell cycle [28], p53 signaling, DNA replication [29], PLK1 signaling [30], and Aurora A/B signaling [31].”
Background
Cited by
The Role of p53 Signaling in Colorectal Cancer
Liebl, M. C., & Hofmann, T. G. (2021) · Cancers · doi:10.3390/cancers13092125 · Cited by 318
Haupt, S., Caramia, F., Herschtal, A., Soussi, T., Lozano, G., Chen, H., Liang, H., Speed, T. P., & Haupt, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-13266-3 · Cited by 94
USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells
Padmanabhan, A., Candelaria, N., Wong, K.-K., Nikolai, B. C., Lonard, D. M., O’Malley, B. W., & Richards, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-03599-w · Cited by 88
Vodicka, P., Andera, L., Opattova, A., & Vodickova, L. (2021) · Cancers · doi:10.3390/cancers13030479 · Cited by 39
“The most frequent classes of TP53 mutations are missense (accounting for 62%), nonsense (14%), and frameshift deletions (9%; for review, see [63]).”
Background
Metadata
- Authors
- Wang, X., & Sun, Q.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-11-21
- Volume
- 8
- Issue
- 1
- Pages
- 624-643
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2552676993
- Cited by
- 132
- References
- 13
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.